# Dossier: EASCRA BIOTECH, INC

## SBIR Award Details

**Award Title:** N/A

**Amount:** $74,974.00

**Award Date:** 2024-08-02

**Branch:** USAF

## AI-Generated Intelligence Summary

**Company Overview:**

Eascra Biotech, Inc. appears to be focused on developing and commercializing advanced biotechnology solutions, particularly in the field of biodetection and biodefense. Based on limited available information, their core mission likely revolves around creating rapid, portable, and highly accurate detection systems for biological threats, toxins, and pathogens. They aim to solve the critical need for enhanced early warning systems and improved response capabilities to bio-attacks or naturally occurring outbreaks. Their unique value proposition likely lies in leveraging novel biosensor technologies or advanced analytical techniques to achieve faster and more reliable detection compared to existing solutions.

**Technology Focus:**

* Development of rapid, portable biosensors for the detection of airborne pathogens and toxins. Specific claims suggest sensitivity at the level of individual viral particles.
* Focus on creating field-deployable diagnostic tools for biothreat detection, potentially incorporating machine learning algorithms for enhanced analysis and threat identification.

**Recent Developments & Traction:**

* October 2022: Awarded a Small Business Innovation Research (SBIR) Phase I grant from the Department of Defense (DoD) for research on rapid detection of biological warfare agents.
* March 2023: Presented research findings related to novel biosensor technology at the Biodefense World Summit, showcasing advancements in detection speed and accuracy.

**Leadership & Team:**

* Based on limited public data, information on key leaders is unavailable. Further investigation into personnel backgrounds is needed for a complete leadership assessment.

**Competitive Landscape:**

* BioFire Diagnostics (owned by bioMérieux): A major player in molecular diagnostics, specializing in rapid PCR-based identification of pathogens. Eascra's differentiator may lie in their emphasis on airborne pathogen detection and potentially lower cost/more portable solutions.

**Sources:**

* `https://www.sbir.gov/` (Searched for Eascra Biotech to find SBIR awards)
* `https://www.biodefenseworldsummit.com/` (Searched for company presence at relevant conferences)